Breast Cancer
Conditions
Keywords
Breast Cancer, Hormone Receptor
Brief summary
The purpose of this study is to see if Positron Emission Tomography (PET) imaging with a radioactive form of the hormone progesterone called FFNP will give the same results as hormone receptor testing already performed on tissue used to diagnose breast cancer.
Interventions
RADIATIONPET
PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
OTHERLaboratory Testing
Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
OTHERSafety Testing
ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
DRUGF18-FFNP
injection of F18-FFNP
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients 18 years of age or older * Biopsy-proven breast cancer * Tumor estrogen-receptor and progesterone-receptor status already determined or scheduled to be determined at time of surgery without intervening therapy. * Primary lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination * Able to give informed consent * Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and / or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), non lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of FFNP) is negative.
Exclusion criteria
* No previous history of hormone therapy; NOTE - subjects who were treated with hormone therapy for reasons other than breast cancer or breast cancer prevention may be allowed to participate after review of history by the primary investigator * Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years * Unable to tolerate 60-90 minutes of PET imaging per imaging session
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy of FFNP-PET imaging compared to in-vivo receptor status | 4 years |
Secondary
| Measure | Time frame |
|---|---|
| To assess the diagnostic quality of FFNP-PET images at the proposed 10.0 mCi dose | 4 years |
| To determine the relationship between tumor FFNP uptake and in vitro status of progesterone receptor | 4 years |
| To calculate human dosimetry and overall safety of FFNP-PET imaging | 4 years |
Countries
United States
Outcome results
None listed